UK Company launches COVID-19 neutralisation assay development kit
pharmafile | April 22, 2021 | News story | | COVID-19
The Native Antigen Company, a supplier of reagents for research into diagnostics and vaccines, have announced the launch of its SARS-CoV-2 Neutralisation Assay Development Kit to be used to identify and qualitatively assess the ability of antibodies to neutralise SARS-CoV-2-receptor binding.
The kit aims to support research into variants and their effects on natural and vaccine-induced patient immunity.
The company has stated that the kit is simple to use and contains all the key reagents required to measure SARS-CoV-2-antibody binding, including the Spike receptor-binding domain (RBD) of the prototypic Wuhan-Hu-1 strain, labelled ACE2, and positive and negative monoclonal antibody controls.
These reagents enable the assessment of neutralising activity of patient and therapeutic antibodies, and can be used alongside company’s range of COVID-19 variant Spike proteins to assess differences in antibody/ACE2 affinities and competitive binding.
Dr Andy Lane, Commercial Director of The Native Antigen Company, said: “This marks The Native Antigen Company’s first release of a dedicated kit for the development of neutralisation assays.
“Our data demonstrates the SARS-CoV-2 Neutralisation Assay Development Kit’s effectiveness and we are confident in its ability to support vital research and development efforts for public health.”
The Native Antigen Company’s in-house data shows that COVID-19 patient sera is able to effectively neutralise the RBD and prevent it from binding to the human ACE2 cell surface receptor.
The Native Antigen Company focuses on the supply of reagents that enable research into vaccine development and diagnostics for emerging and endemic infectious diseases. The company specialises in the development and manufacture of native and recombinant viral and bacterial antigens, antibodies and immunoassays, alongside bespoke product development and custom manufacturing using its proprietary mammalian cell expression system.
Kat Jenkins
Related Content
COVID-19 vaccine eligibility creates challenges for UK pharmacies
Pharmacists across England have reported widespread confusion among patients attempting to book COVID-19 vaccination appointments …
Mental health medicine use in England reaches record high, NHSBSA report reveals
According to new data published by the NHS Business Services Authority (NHSBSA), mental health prescriptions …
FDA approves Moderna’s Spikevax for children at increased risk of COVID-19
Moderna has been granted US Food and Drug Administration (FDA) approval for its COVID-19 vaccine, …
